11![Catheter-Associated Urinary Tract Infection (CAUTI) in Patients >12 Months of Age, 2015 Urine culture with no more than two species of organisms, with at least one organism being a bacteria of >105 CFU/ml No Catheter-Associated Urinary Tract Infection (CAUTI) in Patients >12 Months of Age, 2015 Urine culture with no more than two species of organisms, with at least one organism being a bacteria of >105 CFU/ml No](https://www.pdfsearch.io/img/feade02ce61eab5744db0306b9d1bf26.jpg) | Add to Reading ListSource URL: health.utah.govLanguage: English - Date: 2014-12-18 16:54:06
|
---|
12![Astellas Obtained Approval for Vesicare OD in Japan Tokyo, October 27, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it obtained the approval of ma Astellas Obtained Approval for Vesicare OD in Japan Tokyo, October 27, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it obtained the approval of ma](https://www.pdfsearch.io/img/b477e3d8df8fa1764e7ea322c9bf3b56.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2010-10-26 22:39:57
|
---|
13![June 1, 2006 Astellas Launches “Vesicare®” for the treatment of Overactive Bladder in Japan Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Vesicar June 1, 2006 Astellas Launches “Vesicare®” for the treatment of Overactive Bladder in Japan Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that Vesicar](https://www.pdfsearch.io/img/4977b10fea9a1a147db580e7d24de5cc.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2008-09-19 00:56:17
|
---|
14![June 18, 2010 Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th June 18, 2010 Application for Mirabegron (YM178), a Treatment for OAB, in Japan Tokyo, Japan, June 18, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced th](https://www.pdfsearch.io/img/21b2bc6457286963aa2920d92a76b524.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2010-06-17 22:05:31
|
---|
15![Recovery After Stroke: Bladder & Bowel Function Problems with bladder and bowel function are common but Recovery After Stroke: Bladder & Bowel Function Problems with bladder and bowel function are common but](https://www.pdfsearch.io/img/7202f21715f21f8ac94685ecc281f92b.jpg) | Add to Reading ListSource URL: www.stroke.orgLanguage: English - Date: 1970-01-01 04:13:24
|
---|
16![August 29, 2011 Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As August 29, 2011 Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As](https://www.pdfsearch.io/img/4234c07b4ddf025d53ed988d9b795ae1.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2011-08-26 02:56:51
|
---|
17![September 15, 2011 Astellas Pharma Inc. Launches Betanis® Tablet, a Treatment for OAB, in Japan -Provides a New Option for Patients with OAB Tokyo, Japan, September 15, [removed]Astellas Pharma Inc. (Tokyo:4503,“Astell September 15, 2011 Astellas Pharma Inc. Launches Betanis® Tablet, a Treatment for OAB, in Japan -Provides a New Option for Patients with OAB Tokyo, Japan, September 15, [removed]Astellas Pharma Inc. (Tokyo:4503,“Astell](https://www.pdfsearch.io/img/223378d23c43aa82e315ec5ca1b2492d.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2011-09-14 05:44:33
|
---|
18![MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies NORTHBROOK, Ill., Oct. 22, 2012 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyobased MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies NORTHBROOK, Ill., Oct. 22, 2012 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyobased](https://www.pdfsearch.io/img/2f41cefbf94dcef13ca51ff91a4a79db.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2012-10-22 19:12:22
|
---|
19![Side effects of Prostate Cancer Treatment Type of Treatment Possible Late Complications (Months-Years after Treatment) Side effects of Prostate Cancer Treatment Type of Treatment Possible Late Complications (Months-Years after Treatment)](https://www.pdfsearch.io/img/807896137a3a2fbf11e31a79a22dba75.jpg) | Add to Reading ListSource URL: www.rtanswers.orgLanguage: English - Date: 2014-09-09 09:26:07
|
---|
20![Symptoms (LUTS) in Males: Benign Prostate Hyperplasia…BPH Symptoms (LUTS) in Males: Benign Prostate Hyperplasia…BPH](https://www.pdfsearch.io/img/03c92a5f6c113e3e022979d22b2e1013.jpg) | Add to Reading ListSource URL: bayregionalcancer.comLanguage: English - Date: 2012-07-27 09:40:43
|
---|